Tags : Primary Endpoint

Novartis’ Triple Regimen Fails to Meet the Primary Endpoint in

Shots: The P-III study involves assessing of spartalizumab (PDR001) + Tafinlar (dabrafenib) and Mekinist (trametinib) vs PBO + Tafinlar and Mekinist in previously untreated patients with unresectable or metastatic BRAF V600 mutation-positive melanoma The study was conducted in three parts while today’s results are from part 3 of the trial. The study did not meet […]Read More